Multicell Technologies (MCET) Saham Harga

Multicell Technologies Harga

NYSE·DITUTUP
0,00
​
Pasar ditutup

Selama 19 tahun terakhir pendapatan Multicell Technologies tumbuh 8,8% per tahun, mencapai 49.300,00 USD. Bagi Multicell Technologies, margin bersih sebesar -771,0% naik dibanding -1.314,0% beberapa tahun lalu.

Harga saham Multicell Technologies

Akses data ini lewat Eulerpool API

100.000 permintaan/bulan gratis · tanpa kartu

Model bisnis dan analisis saham Multicell Technologies

Multicell Technologies Inc adalah perusahaan Amerika Serikat yang mengkhususkan diri dalam pengembangan dan produksi produk inovatif di bidang penelitian biomedis dan bioteknologi. Perusahaan ini didirikan pada tahun 1987 oleh sekelompok ilmuwan dan telah memegang posisi terdepan dalam industri sejak saat itu. Mereka mengembangkan teknologi untuk isolasi dan reproduksi buatan kultur sel, berkolaborasi dengan ilmuwan terkemuka dan lembaga penelitian untuk mengembangkan metode dan produk baru dalam memerangi penyakit seperti kanker dan penyakit kardiovaskular, serta menawarkan berbagai produk untuk penelitian biomedis dan bioteknologi, termasuk sistem kultur sel, produk antibodi, dan alat analisis khusus. Mereka juga terlibat dalam produksi garis sel dan kultur, serta mengembangkan terapi aktif, termasuk program pengembangan terapi baru untuk sklerosis multipel. Selain itu, mereka memiliki bisnis diagnostik dan telah mengembangkan platform khusus untuk sekuensing DNA. Secara keseluruhan, Multicell Technologies Inc dikenal karena kolaborasi erat dengan komunitas ilmiah dan dedikasinya dalam mengembangkan produk inovatif untuk bidang medis.

Pertanyaan yang sering diajukan tentang saham Multicell Technologies

The business model of Multicell Technologies Inc revolves around the development and commercialization of innovative therapeutic products for the treatment of neurological disorders, including Multiple Sclerosis (MS), traumatic brain injury (TBI), and spinal cord injury (SCI). The company focuses on utilizing its proprietary platform technology, known as the "MCT-5000," which allows for the creation of specialized cells to facilitate tissue regeneration and repair. Through partnerships and collaborations, Multicell aims to translate its scientific advancements into novel therapeutics that can address unmet medical needs and improve the quality of life for patients.

Multicell Technologies Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Multicell Technologies Inc in the market include other companies in the biotechnology and pharmaceutical industries, particularly those focused on researching and developing innovative therapeutics. Some notable competitors in this space include companies like Amgen, Inc., Gilead Sciences, Inc., Biogen Inc., and Novartis AG. These companies also operate within the healthcare sector and compete in areas such as drug development, clinical trials, market share, and breakthrough therapies.

Multicell Technologies Inc. is a company with a rich history and background. Founded in [insert year], Multicell Technologies has established itself as a leading player in the [insert industry] sector. With a focus on innovation and technological advancements, the company has consistently strived to deliver cutting-edge solutions to its customers. Multicell Technologies Inc. has achieved significant milestones, carving a niche for itself in the market. The company's commitment to quality, customer satisfaction, and continuous growth has propelled its success and garnered a strong reputation in the industry. Multicell Technologies Inc. continues to expand its horizons, aiming to redefine excellence and lead the way in its field.

Multicell Technologies Inc has achieved several significant milestones since its inception. The company has successfully developed innovative biopharmaceutical technologies that have garnered recognition within the industry. Multicell Technologies Inc has also obtained various patents for its groundbreaking discoveries, further solidifying its position as a leading player in the market. With a strong emphasis on research and development, the company has made significant strides in advancing regenerative medicine and cellular therapies. Multicell Technologies Inc's commitment to innovation and breakthrough solutions has enabled it to establish a prominent presence in the field, driving growth and contributing to its success.

Multicell Technologies Inc is primarily present and operates in multiple countries and regions across the globe. With a global footprint, the company has a strong presence in North America, including the United States and Canada. Additionally, Multicell Technologies Inc has established its operations in Europe, covering countries like Germany, France, and the United Kingdom. The company has also expanded its business reach in Asia, specifically in countries such as China, India, and Japan. Being a globally oriented organization, Multicell Technologies Inc aims to leverage its diverse presence to cater to a wide range of markets and serve its clients effectively.

Multicell Technologies Inc represents values of innovation, collaboration, and customer-centricity. With a strong corporate philosophy focused on pushing the boundaries of technology, Multicell strives to develop cutting-edge solutions for a variety of industries. By constantly staying ahead of industry trends, Multicell ensures that it provides the latest and most efficient products to its customers. Recognized for its commitment to quality and excellence, Multicell Technologies Inc is dedicated to delivering exceptional value and customer satisfaction.

Dengan kurs saat ini, saham Multicell Technologies diperdagangkan pada 0,00 EUR (0,00 USD).

Multicell Technologies Inc. is a company specialized in the development and marketing of products in the field of regenerative medicine. The company's business model is based on providing innovative solutions for the treatment of chronic diseases such as diabetes, arthritis, and cancer using human stem cells. The company offers several divisions, including: 1. Therapeutic products: Multicell Technologies has developed a range of therapeutic products made from human stem cells. These products can be used to treat various chronic diseases. For example, Multistem is a therapeutic cell product platform that aims to help manage stem cells in severe diseases such as multiple sclerosis and heart attack. 2. Research products: The company offers a variety of research products, including cell culture systems and molecular diagnostics. These products support research in the fields of regenerative medicine and stem cell therapy. 3. Services: Multicell also provides services such as conducting clinical studies and consulting services for companies operating in the areas of regenerative medicine and stem cell therapy. The company collaborates with leading academic institutions and research facilities to offer its services. Multicell is a pioneer in the production of human stem cell products that help improve the health and quality of life of patients worldwide. The company's products and services are utilized by a variety of customers in the pharmaceutical and biotech industries, as well as in academic research. The company has a strong presence in the USA and aims to expand its products and services to the global market. Multicell is committed to offering innovative solutions in regenerative medicine to contribute to the cure of diseases. Multicell relies on close collaboration with its customers to understand their needs and requirements and offer innovative solutions that can improve the health and well-being of the population worldwide. In conclusion, Multicell Technologies Inc. is an emerging company in the field of regenerative medicine, specializing in the development and marketing of products and services with the aim of treating chronic diseases and contributing to the improvement of global health and quality of life.

Pendapatan tidak dapat dihitung untuk Multicell Technologies saat ini.

Laba tidak dapat dihitung untuk Multicell Technologies saat ini.

PER tidak dapat dihitung untuk Multicell Technologies saat ini.

PSR tidak dapat dihitung untuk Multicell Technologies saat ini.

Skor Kualitas AlleAktien untuk Multicell Technologies adalah 2/10.

ISIN dari Multicell Technologies adalah US62544S2005. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.

WKN dari Multicell Technologies adalah A0ET6A. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.

Ticker dari Multicell Technologies adalah MCET. Simbol ticker digunakan untuk memperdagangkan saham Multicell Technologies di bursa saham.

Nilai WajarTerminal
0,00 USD
Penilaian Berlebihan/KurangTerminal
Dinilai secara wajar
Sektor
Industri
Bioteknologi
Jumlah Saham
Karyawan
Pendapatan per Karyawan
24.650,00 USD
Pertumbuhan Pendapatan Ø5 Tahun
Pertumbuhan EBIT Ø5 Tahun
Pertumbuhan Laba Bersih Ø5 Tahun
Mata Uang
USD
Penawaran Umum Perdana
16 Jun 1994
ISIN
US62544S2005
CUSIP
62544S200
SEDOL
B095CQ5
Kapitalisasi Pasar
37.261,61 USDMicro Cap
Kisaran 52 Minggu
Rasio PEG
—
P/E
P/E
—
P/S
P/S
—
EV/EBIT
—
Rasio P/B
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
656,48 %
Terakhir diperbarui 22 Okt 2026, 12.05

Multicell Technologies FIGI

MCET:US · BBG000DJQRP8MCET:PQ · BBG000DJQYW5MCET:UV · BBG000DJR003